As of 2025-04-24, the Intrinsic Value of CureVac NV (CVAC) is 30.86 USD. This CVAC valuation is based on the model Discounted Cash Flows (Growth Exit 10Y). With the current market price of 3.19 USD, the upside of CureVac NV is 867.40%.
The range of the Intrinsic Value is 18.08 - 70.00 USD
Based on its market price of 3.19 USD and our intrinsic valuation, CureVac NV (CVAC) is undervalued by 867.40%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (53.98) - (17.96) | (26.95) | -944.9% |
| DCF (Growth 10y) | 18.08 - 70.00 | 30.86 | 867.4% |
| DCF (EBITDA 5y) | 65.58 - 121.21 | 91.92 | 2781.5% |
| DCF (EBITDA 10y) | 177.20 - 360.43 | 259.87 | 8046.5% |
| Fair Value | 4.10 - 4.10 | 4.10 | 28.65% |
| P/E | 9.88 - 14.88 | 12.28 | 285.1% |
| EV/EBITDA | 14.49 - 28.58 | 20.03 | 528.0% |
| EPV | (16.33) - (22.73) | (19.53) | -712.2% |
| DDM - Stable | 8.67 - 30.54 | 19.60 | 514.5% |
| DDM - Multi | 42.13 - 117.02 | 62.17 | 1848.9% |
| Market Cap (mil) | 718.26 |
| Beta | 1.64 |
| Outstanding shares (mil) | 225.16 |
| Enterprise Value (mil) | 213.72 |
| Market risk premium | 4.60% |
| Cost of Equity | 8.52% |
| Cost of Debt | 7.83% |
| WACC | 8.48% |